Mauro Saraiva

Dr. Mauro Saraiva

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Advanced Science
Verified
Journal Article
Open access
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
LPLaura Maria Duran Gleriani Primo
Laura Maria Duran Gleriani Primo
KMKaila Petronila Medina-Alarcón
Kaila Petronila Medina-Alarcón
ICIsabella Cardeal Campos
Isabella Cardeal Campos
CNCamila de Fátima Nascimento
Camila de Fátima Nascimento
Fernando AlbericioFernando Albericio
Fernando Albericio
Polymicrobial biofilms adhere to surfaces and enhance pathogen resistance to conventional treatments, significantly contributing to chronic infections in the respiratory tract, oral cavity, chronic wounds, and on medical devices. This review examines antimicrobial peptides (AMPs) as a promising alternative to traditional antibiotics for treating biofilm‐associated infections. AMPs, which can be produced as part of the innate immune response or synthesized therapeutically, have broad‐spectrum antimicrobial activity, often disrupting microbial cell membranes and causing cell death. Many specifically target negatively charged bacterial membranes, unlike host cell membranes. Research shows AMPs effectively inhibit and disrupt polymicrobial biofilms and can enhance conventional antibiotics' efficacy. Preclinical and clinical research is advancing, with animal studies and clinical trials showing promise against multidrug‐resistant bacteria and fungi. Numerous patents indicate increasing interest in AMPs. However, challenges such as peptide stability, potential cytotoxicity, and high production costs must be addressed. Ongoing research focuses on optimizing AMP structures, enhancing stability, and developing cost‐effective production methods. In summary, AMPs offer a novel approach to combating biofilm‐associated infections, with their unique mechanisms and synergistic potential with existing antibiotics positioning them as promising candidates for future treatments.

31 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAndrei I S Souza
Andrei I S Souza
Mauro SaraivaMauro Saraiva
Mauro Saraiva
MCMonique R T Casas
Monique R T Casas
GOGustavo M Oliveira
Gustavo M Oliveira
MCMarita V Cardozo
Marita V Cardozo
ABAngelo Berchieri
Angelo Berchieri
Salmonella Heidelberg is commonly reported in foodborne outbreaks around the world, and chickens and poultry products are known as important source of these pathogen. Multidrug-resistant S. Heidelberg strains are disseminated into poultry production chair, which can lead to severe clinical infections in humans and of difficult to treat. This study aimed at evaluating the β-lactam susceptibility and genotypic relatedness of Salmonella Heidelberg at Brazilian poultry production chain. Sixty-two S. Heidelberg strains from poultry production chain (poultry, poultry meat and poultry farm) were used. All strains were evaluated to antimicrobial susceptibility by diffusion disk test, as well as β-lactam resistance genes. Genotypic relatedness was assessed by Pulsed-Field Gel Eletrophoresis, using Xba1 restriction enzyme. Forty-one strains were characterized as multidrug-resistant according to phenotype characterization. The resistance susceptibility revealed 31 distinct profiles, with higher prevalence of streptomycin (61/62), nalidixic acid (50/62), tetracycline (43/62) and β-lactam drugs (37/62). blaCMY-2 was the more frequent β-lactamase gene found (38/62); other resistance genes found were blaCTX-M (2/62), blaSHV (3/62) and blaTEM-1 (38/62). No carbapenemase genes was found. The Pulsed-Field Gel Electrophoresis showed 58 different profiles. Strains with a larger number of antimicrobial resistance were grouped into ten major clusters apart from others. The spread of resistance by ampC continues to rise, thereby turning concern to public health, since the β-lactam antimicrobials are used as a therapeutic treatment in humans.

1 March 2022 in ACS Infectious Diseases
Verified
Journal Article
Closed access
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Mauro SaraivaMauro Saraiva
Mauro Saraiva
DMDaniel F. M. Monte
Daniel F. M. Monte
LALucas Bocchini Rodrigues Alves
Lucas Bocchini Rodrigues Alves
AAAdriana Maria de Almeida
Adriana Maria de Almeida
Eduardo Festozo VicenteEduardo Festozo Vicente
Eduardo Festozo Vicente

22 December 2022 in Biomaterials
Verified
Journal Article
Closed access
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Mauro SaraivaMauro Saraiva
Mauro Saraiva
WJWagner Dias Macedo Junior
Wagner Dias Macedo Junior
JMJosé Carlos Estanislao Márquez Montesinos
José Carlos Estanislao Márquez Montesinos
AMAndréia Bagliotti Meneguin
Andréia Bagliotti Meneguin
Eduardo Festozo VicenteEduardo Festozo Vicente
Eduardo Festozo Vicente

11 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Mauro SaraivaMauro Saraiva
Mauro Saraiva
AFAlexandre L B Moreira Filho
Alexandre L B Moreira Filho
ONOliveiro de Freitas Neto
Oliveiro de Freitas Neto
NSNúbia Michelle Vieira da Silva
Núbia Michelle Vieira da Silva
PGPatrícia E N Givisiez
Patrícia E N Givisiez
COCelso Oliveira
Celso Oliveira
This trial was designed to evaluate the off-label use of ceftiofur with Marek’s vaccine in one-day-old broiler chicks, a prophylactic treatment that has been done in some commercial hatcheries, on the emergence of extended-spectrum beta-lactamase producing Escherichia coli (ESBL-E. coli). A total of 168 chicks (Cobb500®) were used in a completely randomized design. Birds were assigned to two treatments (Marek’s vaccine plus saline vs Marek’s vaccine plus ceftiofur) and six repetitions, with 14 animals each. Cloacal swabs were collected from 1 to 14 days post-hatch. The majority (86%; p<0.0001) of the ESBL-producing isolates harboring blaCTX-M and blaSHV genes originated from animals receiving the antimicrobial. None of the isolates were positive for plasmid-mediated AmpC betalactamase genes (blaACC, blaCMY-2, blaDHA, blaFOX, blaMOX and blaMIR). These findings indicate that the off-label use of ceftiofur with Marek’s vaccine is associated with the short-term increase in ESBL-producing Escherichia coli in the gut of chicks.

26 November 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
AFAlexandre L. de B. Moreira Filho
Alexandre L. de B. Moreira Filho
COCelso Oliveira
Celso Oliveira
ONOliveiro de Freitas Neto
Oliveiro de Freitas Neto
CLCandice M. C. G. de Leon
Candice M. C. G. de Leon
Mauro SaraivaMauro Saraiva
Mauro Saraiva
PGPatricia Emilia Naves Givisiez
Patricia Emilia Naves Givisiez
This study assessed the effect of in ovo threonine supplementation on the response of broiler chicks challenged with Salmonella Enteritidis, considering bacterial counts in cecal contents, intestinal morphology, body weight, and weight gain. Fertilized eggs were inoculated in the amniotic fluid with saline (NT) or 3.5% threonine (T) solution at day 17.5 of incubation. At hatch, chicks were individually weighed and cloacal swabs were screened for Salmonella. At 2 days of age, half of the birds from each in ovo treatment were given either 0.5 mL of nutrient broth (sham-inoculated) or nalidixic acid-resistant Salmonella Enteritidis (SE NalR) in nutrient broth (8.3 × 107 colony forming units (CFU) SE NalR/mL). The birds were distributed using a completely randomized design with four treatments after the Salmonella challenge: no in ovo Thr supplementation and sham-inoculated in the posthatch challenge (NT-SHAM), in ovo Thr supplementation and sham-inoculated (T-SHAM), no in ovo Thr supplementation and SE NalR-challenged (NT-SE), and in ovo Thr supplementation and SE NalR-challenged (T-SE). In ovo threonine supplementation reduced Salmonella Enteritidis colonization 168-hour postinoculation and reduced the negative effects associated with Salmonella infection on intestinal morphology and performance, with results similar to those of the sham-inoculated birds. In ovo Thr supplementation increased the expression of MUC2 at hatch and the expression of MUC2 and IgA at 2 days of age and 168-hour postinoculation. Our results suggest that providing in ovo threonine promotes intestinal health in broilers challenged with Salmonella Enteritidis in the first days of life.